Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin

Kanako Izumi-Nagai,¹,²,³ Noribiro Nagai,¹,²,⁵ Kazubiro Ogahi,⁴ Shingo Satofuka,¹,² Yoko Ozawa,¹,² Kazuo Tsubota,² Shigeaki Ohno,⁴ Yuichi Oike,¹,⁵ and Susumu Ishida¹,²

PURPOSE. Astaxanthin (AST) is a carotenoid found in marine animals and vegetables. The purpose of the present study was to investigate the effect of AST on the development of experimental choroidal neovascularization (CNV) with underlying cellular and molecular mechanisms.

METHODS. Laser photocoagulation was used to induce CNV in C57BL/6j mice. Mice were pretreated with intraperitoneal injections of AST daily for 3 days before photocoagulation, and treatments were continued daily until the end of the study. CNV response was analyzed by volumetric measurements 1 week after laser injury. Retinal pigment epithelium–choroid levels of iNOS, intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)-1, and VEGFR-2 were examined by Western blotting or ELISA. AST was applied to capillary endothelial (b.End3) cells, macrophages, and RPE cells to analyze the activation of NF-kB and the expression of inflammatory molecules.

RESULTS. The index of CNV volume was significantly suppressed by treatment with AST compared with that in vehicle-treated animals. AST treatment led to significant inhibition of macrophage infiltration into CNV and of the in vivo and in vitro expression of inflammation-related molecules, including VEGF, IL-6, ICAM-1, MCP-1, VEGFR-1, and VEGFR-2. Importantly, AST suppressed the activation of the NF-kB pathway, including iNOS degradation and p65 nuclear translocation.

CONCLUSIONS. AST treatment, together with inflammatory processes including NF-kB activation, subsequent upregulation of inflammatory molecules, and macrophage infiltration, led to significant suppression of CNV development. The present study suggests the possibility of AST supplementation as a therapeutic strategy to suppress CNV associated with AMD.

Disclosure: K. Izumi-Nagai; N. Nagai; N. Ogahi; S. Satofuka; Y. Ozawa; K. Tsubota; S. Ohno; Y. Oike; S. Ishida

From the ¹Laboratory of Retinal Cell Biology and the ²Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan; the ³Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan; and the ⁴Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Corresponding author: Susumu Ishida, Laboratory of Retinal Cell Biology, Department of Ophthalmology, Keio University School of Medicine, 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; ishidasu@sc.iitc.keio.ac.jp.


© 2008 Association for Research in Vision and Ophthalmology

Copyright © Association for Research in Vision and Ophthalmology
spots per eye around the optic disc (wavelength, 532 nm; power, 200 mW; duration, 100 ms; spot size, 75 μm) using a slit lamp delivery system (NOVUS Spectra; Lumenis, Tokyo, Japan), as described previously.7

Treatment with AST
Animals were pretreated with AST (Sigma, St. Louis, MO) or phosphate-buffered saline (PBS) containing 0.1% dimethyl sulfoxide (DMSO) as vehicle daily for 3 days before photocoagulation, and the treatments were continued daily until the end of the study. AST was intraperitoneally administered to mice at the dose of 1, 10, or 100 mg/kg body weight (BW).

Quantification of Laser-Induced CNV
One week after laser injury, eyes were enucleated and fixed with 4% paraformaldehyde (PFA). Eyecups obtained by removing anterior segments were incubated with 0.5% fluorescein-isothiocyanate (FITC)-isolectin B4 (Vector, Burlingame, CA). CNV was visualized with blue argon laser wavelength (488 nm) using a scanning laser confocal microscope (FV1000; Olympus, Tokyo, Japan). Horizontal optical sections of CNV were obtained at every 1-μm step, from the surface to the deepest focal plane. The area of CNV-related fluorescence was measured by National Institutes of Health Image software. Summation of the whole fluorescence area was used as the index of CNV volume, as described previously.7

Immunohistochemistry for Infiltrating Macrophages
Wholemount choroid-sclera complexes obtained 3 days after photocoagulation and reverse transcribed. Quantitative polymerase chain reaction (PCR) analyses for F4/80 and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) were performed in a real-time PCR system (ABI 7500 Fast; Applied Biosystems, Foster, CA) in combination with an ECL kit (GE Healthcare, Buckinghamshire, UK) according to the manufacturer’s protocol.

In Vitro Assays
We examined the in vitro effect of AST on inflammatory responses from three major cell types associated with CNV formation—vascular endothelial cells, macrophages and RPE cells—using the murine cell lines b-END3 and RAW264.7 and the human cell line ARPE-19, respectively. Cells were pretreated with AST (50 or 150 μM) or vehicle in serum-starved DMEM for b-END3 and RAW264.7 cells or DMEM/F12 (Sigma) for ARPE-19 cells. Pretreated cells were then stimulated with tumor necrosis factor (TNF)-α (10 ng/mL for b-END3 cells and 20 ng/mL for ARPE-19 cells; Sigma) or LPS (200 ng/mL for RAW264.7 cells; Sigma) plus AST (50 or 150 μM) or vehicle. After 30-minute incubation, the cell lysates were processed for Western blot analyses for IκB-α. After 6-hour incubation, the cell lysate from b-END3 and RAW264.7 cells were processed for ELISA for ICAM-1, VEGFR-2, and VEGFR-1. Supernatants from b-END3 and RAW264.7 cells were processed for ELISA for MCP-1, IL-6, and VEGF. After 24-hour incubation, the supernatant from ARPE-19 cells was processed for ELISA for MCP-1 and VEGF.

Immunocytochemistry for NF-κB p65
After 24-hour pretreatment with AST (150 μM) or vehicle in serum-starved DMEM for b-END3 cells and RAW264.7 cells or DMEM/F12 for ARPE-19 cells, cells were incubated with TNF-α (10 ng/mL for b-END3 cells and 20 ng/mL for ARPE-19 cells) or LPS (200 ng/mL for RAW264.7 cells; Sigma) with AST (150 μM) or vehicle for 30 minutes. Immunocytochemical analyses for NF-κB p65 were performed, as described previously.24 Each average ratio of the number of cells with nuclear p65 staining to the number of total cells per microscopic field was analyzed.

Statistical Analyses
All results were expressed as mean ± SD. The values were processed for statistical analyses (Mann-Whitney U test). Differences were considered statistically significant at P < 0.05.

RESULTS
Suppression of CNV in Mice Receiving AST
The index of CNV volume was measured to evaluate the effects of AST treatment on the development of CNV. CNV was significantly suppressed by treatment with AST. AST-treated mice, at the dose of 10 or 100 mg/kg BW, showed a significant decrease in the index of CNV volume (464,738 ± 87,719 μm³ for 10 mg/kg BW and 431,321 ± 77,538 μm³ for 100 mg/kg BW) compared with vehicle-treated mice (591,283 ± 82,688 μm³; Figs. 1A, 1B).

Suppression of Macrophage Infiltration by Treatment with AST
As the cellular mechanism in the pathogenesis of CNV, the infiltration of inflammatory cells, including macrophages, plays a critical role in the growth of CNV. We analyzed the infiltration of macrophages in murine CNV by immunohistochemistry (Fig. 2A) and quantitative RT-PCR (Fig. 2B) for the macrophage-specific antigen F4/80. Immunoreactivity for F4/80 was substantially lower in AST-treated mice at the dose of 10 or 100 mg/kg BW than in vehicle-treated mice (Fig. 2A). In the quantitative analyses using the real-time PCR, AST-treated mice at
the dose of 10 or 100 mg/kg BW showed a significant decrease in the expression of F4/80 in the RPE–choroid complex compared with vehicle-treated animals (P < 0.01; Fig. 2B).

**In Vivo Inhibition of Inflammatory and Angiogenic Molecules by the Treatment with AST**

To determine whether AST treatment affects inflammatory and angiogenic molecules related to the pathogenesis of CNV, protein levels of ICAM-1, MCP-1, IL-6, VEGF, VEGFR-1, and VEGFR-2 in the RPE–choroid complex were analyzed by ELISA. RPE–choroid levels of ICAM-1, MCP-1, IL-6, VEGF and VEGFR-1 were significantly higher in mice with CNV than in age-matched healthy controls. AST treatment significantly suppressed protein levels of ICAM-1, MCP-1, IL-6, VEGF, VEGFR-1 and VEGFR-2 (Figs. 3A–F).

**In Vitro Inhibition of Inflammatory and Angiogenic Molecules by Treatment with AST**

To confirm in vivo effects of AST on choroidal inflammation and neovascularization, we further performed in vitro analyses. In RAW264.7 macrophages, AST treatment significantly (P < 0.01) reduced the protein levels of LPS-induced IL-6 (Fig. 4A) and VEGFR-2 (Fig. 4B). In ARPE-19 cells, AST application led to a significant (P < 0.01) decrease in the protein levels of TNF-α-induced MCP-1 (Fig. 4C). Similarly, in b-End3 cells, AST treatment significantly (P < 0.01) reduced protein levels of MCP-1 (Fig. 4D), ICAM-1 (Fig. 4E), and VEGFR-2 (Fig. 4F), all of which were induced by TNF-α. In contrast, VEGF production was not significantly changed by treatment with AST, either in RAW264.7 macrophages or in ARPE-19 cells (data not shown).

**In Vivo Inhibition of NF-κB Activation by Treatment with AST**

To define the signaling pathway involved in treatment with AST, we focused on NF-κB as an upstream transcriptional factor of inflammatory mediators and analyzed the protein level of 1xB-α in vivo. In the murine RPE–choroid tissues, photocoagulation induced NF-κB activation, including 1xB-α degradation (Figs. 5A, 5B). Protein levels of 1xB-α in the RPE–choroid complex were significantly (P < 0.01) reduced 4 hours after photocoagulation compared with age-matched healthy controls. AST significantly (P < 0.01) inhibited 1xB-α degradation at 4 hours in the murine RPE–choroid complex (Figs. 5A, 5B).

**In Vitro Inhibition of NF-κB Activation by Treatment with AST**

To further confirm in vivo effects of AST on NF-κB inhibition, we performed in vitro experiments using RAW264.7, ARPE-19, and b-End3 cells stimulated by LPS or TNF-α. AST significantly (P < 0.05) inhibited 1xB-α degradation enhanced by LPS in RAW264.7 cells (Figs. 6A, 6B) or by TNF-α in ARPE-19 cells (Figs. 6C, 6D) and b-End3 cells (Figs. 6E, 6F). Nuclear translocation of NF-κB p65, enhanced by TNF-α or LPS, was significantly (P < 0.01) suppressed by the application of AST in RAW264.7 cells (Figs. 7A, 7B), ARPE-19 cells (Figs. 7C, 7D), and b-End3 cells (Figs. 7E, 7F).

**DISCUSSION**

The present study reveals several important findings concerning the antipathogenic role of AST in the development of CNV. First, treatment with AST led to significant suppression of CNV (Fig. 1). Second, the cellular and molecular mechanisms in AST treatment included the inhibitory effects on macrophage infiltration into CNV (Fig. 2) and inflammation-related molecules in the RPE–choroid complex (Fig. 3) and in cultured macrophages, RPE cells, and microvascular endothelial cells (Fig. 4). Third, AST treatment resulted in the inhibition of NF-κB activation in vivo (Fig. 5) and in vitro (Figs. 6, 7).
Various observational\textsuperscript{25–27} and interventional\textsuperscript{28,29} studies showed the possibility of carotenoid consumption, including AST,\textsuperscript{28} lutein,\textsuperscript{25,26,29} and \(\beta\)-carotene,\textsuperscript{27} for reducing the risk for AMD. Accordingly, the effect of carotenoid supplementation for preventing and treating AMD has recently been attracting attention. We have revealed that lutein is anti-inflammatory in preventing CNV in mice.\textsuperscript{23} AST has higher antioxidant activity toward peroxyl radicals than lutein.\textsuperscript{30} However, no data have been presented concerning the inhibitory effect of AST on CNV development. We have demonstrated for the first time that AST treatment led to the suppression of CNV (Fig. 1).

As cellular mechanisms for suppressing CNV by the treatment with AST, the present data showed that AST application led to significant suppression of macrophage infiltration (Fig. 2). Pharmacologic depletion of macrophages, which accumulated in murine CNV tissues,\textsuperscript{31} resulted in significant suppression of murine CNV.\textsuperscript{7,9} One of roles of macrophages in the development of CNV is to promote neovascularization by se-

\[\text{Figure 3. Inhibitory effects of AST on RPE-choroid production of inflammatory and angiogenic molecules (A-F). AST significantly suppressed protein levels of ICAM-1 (A), MCP-1 (B), IL-6 (C), VEGF (D), VEGFR-1 (E), and VEGFR-2 (F) in the RPE choroids. } n = 8. *P < 0.05; **P < 0.01.\]

\[\text{Figure 4. In vitro effects of AST on protein levels of inflammatory and angiogenic molecules in RAW264.7 macrophages (A, B), ARPE-19 cells (C), and b-End5 microvascular endothelial cells (D-F). AST significantly reduced protein levels of IL-6 (A), VEGFR-1 (B), MCP-1 (C, D), ICAM-1 (E), and VEGFR-2 (F). } n = 8. *P < 0.05; **P < 0.01.\]
creting VEGF at the lesion where RPE and vascular endothelial cells produce MCP-1 for macrophage recruitment. Our present data are compatible with the recent data showing that AST application led to in vivo suppression of inflammatory cell infiltration in the rodent model of endotoxin-induced uveitis and in the rabbit model of atherosclerosis. As molecular mechanisms for suppressing CNV, the present data showed the AST-induced suppression of various inflammation-related molecules, including VEGF, VEGFR-1, VEGFR-2, IL-6, ICAM-1, and MCP-1, which were upregulated after the induction of CNV (Fig. 3). Previous reports concerning the molecular mechanisms underlying CNV generation showed VEGF as a promoting mediator. Macrophages infiltrating into CNV are a rich source of VEGF. VEGFR-1 is expressed in inflammatory leukocytes, including macrophages. The AST-induced decrease in RPE–choroid VEGF and VEGFR-1, seen in the present study (Fig. 3), is compatible with and is explained at least in part by the suppression of VEGF-secreting and VEGFR-1-bearing macrophage infiltration. Indeed, our in vitro experiments (Fig. 4) showed no remarkable effects on VEGF production either in macrophages or in RPE cells after AST treatment (data not shown). Additionally, we performed in vitro experiments showing that IL-6 levels in macrophages, MCP-1 levels in RPE cells, and ICAM-1, MCP-1, and VEGFR-2 levels in vascular endothelial cells were significantly reduced by AST (Fig. 4). Recently, we have shown that CNV formation is mediated by IL-6 receptor signaling. Several in vivo experiments with genetically altered mice demonstrated a significant contribution of adhesion molecules and chemotactic factors, including ICAM-1 and MCP-1, both of which are required for macrophage infiltration. VEGF-mediated endothelial cell mitogenic activity was shown to depend on VEGFR-2. Collectively, the presently observed suppression of CNV by treatment with AST is likely attributable to the inhibition of multiple inflammatory steps, including MCP-1–induced migration and ICAM-1-dependent adhesion of macrophages, subsequent macrophage-derived VEGF and IL-6 secretion, and VEGFR-2 expression in endothelial cells.

Because NF-κB is suggested to induce the expression of inflammation-related molecules, we investigated the role of NF-κB in the development of CNV (Figs. 5-7). After IκB phosphorylation and degradation caused by various stimuli, NF-κB p65/p50, capable of entering the nucleus and binding the κB sequence, promotes the transcription of target genes including ICAM-1, MCP-1, and IL-6. Recently, we have clarified the critical role of NF-κB in the development of CNV, showing the NF-κB inhibition with an inhibitor of p65 nuclear translocation (dehydroxymethylepoxyquinomicin) led to significant suppression of experimental CNV. In the present study, AST inhibited the activation of NF-κB by suppressing IκB degradation (Figs. 5, 6) and subsequent p65 nuclear translocation (Fig. 7) in the RPE–choroid in vivo (Fig. 5) and in macrophages, RPE cells, and microvascular endothelial cells (Figs. 6, 7). Collectively, our data suggest the importance of AST capable of inhibiting NF-κB activation.
Anti-VEGF therapy is applied for the treatment of AMD complicated by CNV. Because the therapeutic intervention for blocking VEGF tends to be limited to the advanced stage, an alternative early treatment is thought to be required, targeting inflammation as an antecedent event leading to neovascularization. Epidemiologic risk factors for AMD include age, smoking, cardiovascular diseases such as atherosclerosis, and nutrient status. It is reasonable to intervene modifiable risk factors, such as nutrient status for the prevention of AMD. Accordingly, our present data may provide molecular evidence of the potential validity of AST supplementation as a therapeutic strategy to suppress CNV.

References

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900–1901.


